7.22.2014GALTGalectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination of Ipilimumab in Metastatic Melanoma
7.11.2014GALTGalectin Therapeutics Added To Russell 2000 Index
6.24.2014GALTGalectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 Is Efficacious In Preclinical Model Of Fatty Liver Disease With Fibrosis
5.30.2014GALTGalectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference
5.28.2014GALTGalectin Therapeutics Receives U.S. Patent For GR-MD-02 In Diabetic Nephropathy, A Progressive Kidney Disease
5.14.2014GALTView a Presentation from the 2014 Annual Stockholder Meeting
5.14.2014GALTGalectin Therapeutics Reports First Quarter 2014 Financial Results
5.12.2014NFRANFRA Announces National Advisory Board
5.9.2014MURRNorthwest Medical Isotopes Invests $50 Million In Columbia, Missouri, Radioisotope Production Facility
5.8.2014GALTGalectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders
4.23.2014GALTGalectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis
4.17.2014GALTGalectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis
4.1.2014GALTFirst Cohort Results in Galectin Therapeutics’ Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis
2.13.2014GALTGalectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference
2.10.2014GALTGalectin Therapeutics Statement on Life Sciences Advisors Report on La Jolla Pharmaceuticals
2.7.2014GALTGalectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma
2.5.2014GALTGalectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
1.28.2014GALTGalectin Therapeutics Inc. & SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC
1.21.2014GALTPreclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis
1.13.2014GALTGalectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
1.10.2014GALTGalectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million
1.8.2014GALTGalectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity
1.6.2014GALTGalectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis
12.19.2013GALTPublished Preclinical Study Demonstrates Therapeutic Effect of Galectin Inhibitors in Fatty Liver Disease With Fibrosis
11.6.2013Global PET ImagingHoping to Help Heart Attack Patients, MU Signs Agreement With Global PET
11.4.201310X Fund10X Fund Issues Statement on Exercise of Additional 200,000 Galectin Therapeutics Warrants
10.17.201310X Fund10X Fund Issues Statement on Sale of Shares, Bullish Outlook Regarding Galectin Therapeutics
10.10.2013GALTGalectin Therapeutics' Preclinical Data Published in PLOS ONE Show Its Galectin Inhibitors Reverse Cirrhosis and Significantly Reduce Fibrosis and Portal Hypertension
8.15.13GALTGalectin Therapeutics Reports Second Quarter 2013 Financial Results
8.12.2013GALTGalectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis
8.5.2013GALTReduction in Lung Fibrosis with the Anti-Galectin Drug GR-MD-02 Revealed in Preclinical Data
7.24.2013GALTGalectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
5.15.2013GALTGalectin Therapeutics to Hold Conference Call to Provide Update Following Company’s Annual Meeting of Shareholders
5.10.2013GALTGalectin Therapeutics Reports First Quarter 2013 Financial Results
4.29.2013GALTGalectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies
4.17.2013GALTGalectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and Cirrhosis
4.9.2013GALTClinical Trial Sites for First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis Announced by Galectin Therapeutics
3.5.2013GALTGalectin Therapeutics Inc. Receives OK from FDA to Proceed with First Human Clinical Trial for Treatment of Fatty Liver Disease with Advanced Fibrosis
2.19.2013GALTGalectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia
2.1.2013GALTGalectin Submits IND For GR-MD-02
1.31.2013GALTGalectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease
1.29.2013GALTGALT To Be Featured On New Show On Fox Business News
1.22.2013GALTNew Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in Preclinical Studies